@article{cb5d40d09ccc41a49c9d153f93c71699,
title = "Genomic landscapes of EBV-associated nasopharyngeal carcinoma vs. HPV-associated head and neck cancer",
abstract = "Epstein-Barr virus-positive nasopharyngeal carcinoma (EBV(+) NPC), and human papillomavirus-positive head and neck squamous cell carcinoma (HPV(+) HNSCC) are two distinct types of aggressive head and neck cancers with early age onsets. Their recently identified genomic landscapes by whole-exome sequencing (WES) clearly reveal critical roles of: (1) inflammation via NF-kB activation, (2) survival via PI3K aberrations, and perhaps (3) immune evasion via MHC loss in these cancers as summarized in this review. Immediate outcomes of these WES studies include the identification of potential prognostic biomarkers, and druggable events for these cancers. The impact of these genomic findings on the development of precision medicine and immunotherapies will be discussed. For both of these cancers, the main lethality comes from metastases and disease recurrences which may represent therapy resistance. Thus, potential curing of these cancers still relies on future identification of key genomic drivers and likely druggable events in recurrent and metastatic forms of these intrinsically aggressive cancers of the head and neck.",
keywords = "EBV(+) NPC, Genomic profiles, HPV(+) HNSCC",
author = "Ngan, {Hoi Lam} and Lan Wang and Lo, {Kwok Wai} and Lui, {Vivian Wai Yan}",
note = "Funding Information: This research was funded by the Research Grant Council, Hong Kong, grant number 17114814, 17121616, 14168517, 470312, 1404415, 14138016, 14117316, 14104415, and 1413016, Theme-based Research Scheme T12-401/13-R; by Faculty of Medicine, the Chinese University of Hong Kong, direct grant for research number 2016.095, Focused Innovations Scheme and Faculty Strategic Research grant number 4620513; and The Chinese University of Hong Kong, Start-up Fund from the School of Biomedical Sciences, and Core Utilities of Cancer Genome and Pathobiology, and VC{\textquoteright}s One-off Discretionary Fund grant number VCF2014017 and VCF2014015; and Hong Kong government (Innovation and Technology Fund) and Lee{\textquoteright}s Pharmaceutical (HK) Limited for University Industry Collaboration Program grant number UIM/329. We acknowledge the generation donation of the Hong Kong Cancer Fund to support our research (to V.W.Y.L.). Funding Information: Conflicts of Interest: V.W.Y.L. receives a research funding (UIM/329) through University Industry Collaboration Program by the Innovation Technology Fund, Hong Kong government and Lee{\textquoteright}s Pharmaceutical (HK) Limited. The other authors declare no conflict of interest. Funding Information: Funding: This research was funded by the Research Grant Council, Hong Kong, grant number 17114814, 17121616, 14168517, 470312, 1404415, 14138016, 14117316, 14104415, and 1413016, Theme-based Research Scheme T12-401/13-R; by Faculty of Medicine, the Chinese University of Hong Kong, direct grant for research number 2016.095, Focused Innovations Scheme and Faculty Strategic Research grant number 4620513; and The Chinese University of Hong Kong, Start-up Fund from the School of Biomedical Sciences, and Core Utilities of Cancer Genome and Pathobiology, and VC{\textquoteright}s One-off Discretionary Fund grant number VCF2014017 and VCF2014015; and Hong Kong government (Innovation and Technology Fund) and Lee{\textquoteright}s Pharmaceutical (HK) Limited for University Industry Collaboration Program grant number UIM/329. Publisher Copyright: {\textcopyright} 2018 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2018",
month = jul,
doi = "10.3390/cancers10070210",
language = "English (US)",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",
}
